EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieVergleichsstudie

177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial

Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R Chandekar, Chandan K Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Jaya Shukla und 2 weitere

Journal of Nuclear Medicine · 2025-02 · 66 (2) · 238-244

DOI: 10.2967/jnumed.124.268617 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.01.2025. Verfasst von Swayamjeet Satapathy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Capecitabine, Neuroendocrine Tumors, Organometallic Compounds, Octreotide. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineNeuroendocrine TumorsOrganometallic CompoundsOctreotidePancreatic NeoplasmsStomach NeoplasmsIntestinal NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultNeoplasm GradingTreatment Outcome

Stichwörter der Autor:innen

177Lu-DOTATATEGEP-NETscapecitabineradiosensitizer

Substanzen

CapecitabineOrganometallic Compoundslutetium Lu 177 dotatateOctreotide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India; sood99@yahoo.com.
  • Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Montefiore Medical Center, Bronx, New York.
  • Department of GI Surgery, HPB and Liver Transplantation, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Zitieren

APA

Satapathy, S., Aggarwal, P., Sood, A., Chandekar, K. R., Das, C. K., Gupta, R., Khosla, D., Das, N., Kapoor, R., Kumar, R., Singh, H., Shukla, J., Kumar, A., & Mittal, B. R. (2025). 177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. Journal of Nuclear Medicine, 66(2), 238-244. https://doi.org/10.2967/jnumed.124.268617

Vancouver

Satapathy S, Aggarwal P, Sood A, Chandekar KR, Das CK, Gupta R, et al. 177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. Journal of Nuclear Medicine. 2025;66(2):238-244. doi:10.2967/jnumed.124.268617

BibTeX
@article{Satapathy2025,
  author = {Satapathy, Swayamjeet and Aggarwal, Piyush and Sood, Ashwani and Chandekar, Kunal R and Das, Chandan K and Gupta, Rajesh and Khosla, Divya and Das, Namrata and Kapoor, Rakesh and Kumar, Rajender and Singh, Harmandeep and Shukla, Jaya and Kumar, Ajay and Mittal, Bhagwant Rai},
  title = {177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {2},
  pages = {238--244},
  doi = {10.2967/jnumed.124.268617}
}
Kostenlos starten →